BackgroundPatients with bipolar disorder are often unrecognised and misdiagnosed with major depressive disorder leading to higher direct costs and pressure on the medical system. Novel screening tools may mitigate the problem. This study was aimed at investigating the direct costs of bipolar disorder misdiagnosis in the general population, evaluating the impact of a novel bipolar disorder screening algorithm, and comparing it to the established Mood Disorder Questionnaire. A decision analysis model was built to quantify the utility of one-time screening for bipolar disorder in primary care adults presenting with a depressive episode. A hypothetical population of interest comprised a healthcare system of one million users, corresponding to 15,000 help-seekers diagnosed with major depressive disorder annually, followed for five years. The model was used to calculate the impact of screening for bipolar disorder, compared to no screening, in terms of accuracy and total direct costs to a third-party payer at varying diagnostic cut-offs. Decision curve analysis was used to evaluate clinical utility.ResultsCompared to no screening, one-time screening for bipolar disorder using the algorithm reduced the number of misdiagnoses from 680 to 260, and overall direct costs from $50,936 to $49,513 per patient, accounting for $21.3 million savings over the five-year period. The algorithm outperformed the Mood Disorder Questionnaire, which yielded 367 misdiagnoses and $18.3 million savings over the same time. Decision curve analysis showed the screening model was beneficial.ConclusionsUtilisation of bipolar disorder screening strategies could lead to a substantial reduction in human suffering by reducing misdiagnosis, and also lessen the healthcare costs.